triple glp-1/gip/glucagon receptor agonist LY3437943, a novel glucagon, GIP, and GLP-1 for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor
Description
These include: Nausea Vomiting Diarrhoea Constipation Abdominal pain These side effects are typically mild to moderate, most common when starting the medication or increasing the dose, and often subside over time
If skin doesnt snap back quickly it can be an indicator of low hydration
Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery
GLP-1 medicines induce substantial metabolic improvements in the liver, with reduction in liver weight and lipid accumulation largely attributed to weight loss
The first GLP-1RA was approved by the FDA (U.S
